InsiderClue
← All stocks

Septerna, Inc.

SEPN Net buying
CIK 0001984086 #2087 in the set updated 17 Sep 2026
Bought (120 mo)
$93.97M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$76.05M
$7.40M on a plan · $5.14M straight out of an exercise
Sold at will
$63.52M
3 of 27 sales
Net
+$17.92M
+$30.46M against sales at will

By person

10 insiders · 51 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
RA CAPITAL MANAGEMENT, L.P. entity
Director
$75.06M (2)
$63.45M (2)
+$11.61M
725,443
1.55%
$27.44M
—
Third Rock Ventures VI, L.P. entity
10% owner
$6.28M (3)
—
+$6.28M
4,211,659
9.02%
$159.31M
+33.6%
Third Rock Ventures V, L.P. entity
10% owner
$11.70M (2)
$7.40M (2) scheduled
+$4.30M
9,220,847
19.75%
$348.80M
+1,113%
Shaikhly Samira
Chief People Officer
—
$2.80M (8) scheduled
−$2.80M
793
0.0017%
$30.00K
0.0%
Bhatt Elizabeth
President and COO
—
$1.45M (7) scheduled
−$1.45M
174,209
0.3732%
$6.59M
0.0%
Long Daniel D.
SVP, Drug Discovery
—
$951.33K (8) scheduled
−$951.33K
96,412
0.2066%
$3.65M
−3.5%
Ezekowitz Alan
Director
$608.20K (4)
—
+$608.20K
117,420
0.2516%
$4.44M
+574.1%
Labrucherie Gil M
Chief Financial Officer
$229.16K (5)
—
+$229.16K
40,000
0.0857%
$1.51M
—
Finer Jeffrey
Chief Executive Officer
$96.96K (3)
—
+$96.96K
826,907
1.77%
$31.28M
+9.5%
Klein Uwe
SVP, Biological Sciences
—
—
—
23,008
0.0493%
$870.33K
—

Individual transactions

51
Insider
Date
Role
Action
Shares
Price
Amount
Long Daniel D.
1 Sep 2026
SVP, Drug Discovery
Sold after exercise
3,333
$37.83
$126.08K
RA CAPITAL MANAGEMENT, L.P.
12 Aug 2026
Director
Sell indirect
746,500
$42.50
$31.73M
RA CAPITAL MANAGEMENT, L.P.
12 Aug 2026
Director
Sell indirect
746,500
$42.50
$31.73M
Third Rock Ventures V, L.P.
12 Aug 2026
10% owner
Sold on a plan
141
$51.08
$7.20K
Third Rock Ventures V, L.P.
12 Aug 2026
10% owner
Sold on a plan
147,059
$50.27
$7.39M
Bhatt Elizabeth
11 Aug 2026
President and COO
Sold after exercise
25,000
$44.00
$1.10M
Long Daniel D.
3 Aug 2026
SVP, Drug Discovery
Sold after exercise
2,334
$34.68
$80.94K
Long Daniel D.
3 Aug 2026
SVP, Drug Discovery
Sold after exercise
1,000
$33.98
$33.98K
Bhatt Elizabeth
15 Jul 2026
President and COO
Sold after exercise
4,000
$33.99
$135.97K
Long Daniel D.
1 Jul 2026
SVP, Drug Discovery
Sold after exercise
1,233
$34.81
$42.93K
Long Daniel D.
1 Jul 2026
SVP, Drug Discovery
Sold after exercise
2,100
$34.10
$71.60K
Shaikhly Samira
29 Jun 2026
Chief People Officer
Sold after exercise
2,178
$35.18
$76.62K
Long Daniel D.
22 Jun 2026
SVP, Drug Discovery
Sold after exercise
7,000
$35.97
$251.78K
Long Daniel D.
22 Jun 2026
SVP, Drug Discovery
Sold after exercise
8,000
$35.10
$280.80K
Shaikhly Samira
12 Jun 2026
Chief People Officer
Sold after exercise
6,250
$35.08
$219.22K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
2,889
$29.66
$85.70K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
1,346
$28.79
$38.76K
Shaikhly Samira
1 Jun 2026
Chief People Officer
Sold after exercise
1,700
$27.78
$47.23K
Shaikhly Samira
26 May 2026
Chief People Officer
Sold after exercise
11,798
$30.06
$354.66K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
326
$25.86
$8.43K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
1,101
$25.24
$27.79K
Bhatt Elizabeth
15 Apr 2026
President and COO
Sold after exercise
2,573
$23.76
$61.12K
Shaikhly Samira
2 Mar 2026
Chief People Officer
Sold after exercise
66,363
$28.14
$1.87M
Shaikhly Samira
2 Mar 2026
Chief People Officer
Sold after exercise
4,090
$27.51
$112.50K
Bhatt Elizabeth
18 Feb 2026
President and COO
Sold after exercise
1,800
$29.58
$53.25K
Bhatt Elizabeth
18 Feb 2026
President and COO
Sold after exercise
2,200
$28.46
$62.61K
Long Daniel D.
10 Nov 2025
SVP, Drug Discovery
Sell
3,501
$18.06
$63.22K
Klein Uwe
18 Aug 2025
SVP, Biological Sciences
Exercised, kept
7,621
$6.81
$51.90K
Klein Uwe
18 Aug 2025
SVP, Biological Sciences
Exercised, kept
4,935
$2.76
$13.62K
Klein Uwe
18 Aug 2025
SVP, Biological Sciences
Exercised, kept
10,452
$2.76
$28.85K
Finer Jeffrey
3 Apr 2025
CEO and President
Exercised, kept
5,000
$2.76
$13.80K
Finer Jeffrey
2 Apr 2025
CEO and President
Exercised, kept
50,000
$2.76
$138.00K
Ezekowitz Alan
7 Mar 2025
Director
Buy
13,319
$6.93
$92.27K
Ezekowitz Alan
6 Mar 2025
Director
Buy
41,355
$6.00
$248.13K
Ezekowitz Alan
5 Mar 2025
Director
Buy
37,835
$5.82
$220.26K
Ezekowitz Alan
4 Mar 2025
Director
Buy
7,491
$6.35
$47.54K
Labrucherie Gil M
27 Feb 2025
Chief Financial Officer
Buy indirect
3,718
$5.85
$21.75K
Finer Jeffrey
27 Feb 2025
CEO and President
Buy
3,000
$5.80
$17.40K
Finer Jeffrey
26 Feb 2025
CEO and President
Buy
4,000
$5.70
$22.80K
Labrucherie Gil M
25 Feb 2025
Chief Financial Officer
Buy indirect
6,282
$5.59
$35.12K
Finer Jeffrey
25 Feb 2025
CEO and President
Buy
10,000
$5.68
$56.77K
Third Rock Ventures VI, L.P.
24 Feb 2025
10% owner
Buy
18,861
$6.00
$113.15K
Labrucherie Gil M
21 Feb 2025
Chief Financial Officer
Buy indirect
5,000
$5.85
$29.25K
Third Rock Ventures VI, L.P.
21 Feb 2025
10% owner
Buy
427,668
$5.94
$2.54M
Labrucherie Gil M
20 Feb 2025
Chief Financial Officer
Buy indirect
14,500
$5.88
$85.23K
Third Rock Ventures VI, L.P.
20 Feb 2025
10% owner
Buy
612,674
$5.92
$3.63M
Labrucherie Gil M
19 Feb 2025
Chief Financial Officer
Buy indirect
10,500
$5.51
$57.81K
Third Rock Ventures V, L.P.
28 Oct 2024
10% owner
Buy indirect
279,500
$18.00
$5.03M
Third Rock Ventures V, L.P.
28 Oct 2024
10% owner
Buy
370,500
$18.00
$6.67M
RA CAPITAL MANAGEMENT, L.P.
28 Oct 2024
Director
Buy indirect
341,600
$18.00
$6.15M
RA CAPITAL MANAGEMENT, L.P.
28 Oct 2024
Director
Buy indirect
3,828,400
$18.00
$68.91M

What was left out

Form 4 filings counted 60
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 8
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 22
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 10,726,209
History held since 28 Oct 2024